Invivogen
Menu

HCT116-Dual™ Cells

HCT116-Dual™ Cells Unit size Cat. code Docs Qty Price
Human NF-κB-SEAP & IRF-Luc Reporter colorectal carcinoma
3-7 x 10e6 cells
hctd-nfis
+-
$1,142.00

Human HCT116 colorectal carcinoma - NF-κB & IRF reporter cells

HCT116-Dual™ cells are adherent epithelial cells that have been derived from the human HCT116 colorectal carcinoma cell line by stable integration of two inducible reporter constructs.

HCT116-Dual™ cells  express a secreted embryonic alkaline phosphatase (SEAP) reporter gene under the control of the IL-12 p40 minimal promoter fused to five NF-κB and AP-­1 binding sites.

HCT116-Dual™ cells also express the Lucia luciferase gene, which encodes a secreted luciferase, under the control of an ISG54 minimal promoter in conjunction with five IFN-stimulated response elements.

As a result, HCT116-Dual™ cells allow to simultaneously study the NF-κB pathway, by assessing the activity of SEAP, and the interferon regulatory factor (IRF) pathway, by monitoring the activity of Lucia luciferase.

Both reporter proteins are readily measurable in the cell culture supernatant when using QUANTI-Blue™, a SEAP detection reagent, and QUANTI-Luc™, a Lucia luciferase detection reagent.

Figures


Stimulation of HCT116-Dual™ cells with the following PAMPs, Tri-DAP (NOD1 ligand, 10 µg/ml), FLA-ST Ultrapure (TLR5, 1 µg/ml), MDP (10 µg/ml), and Poly(I:C) (TLR3 ligand, 1 µg/ml) leads to the activation of NF-κB. IL-1β (100 ng/ml) has been included as positive controls to activate the NF-κB signaling pathway. Non-induced cells (NI), the TLR2 ligand (Pam3CSK4; 300 ng/ml), and the TLR4 ligand (LPS-EB Ultrapure; 104 EU/ml) have been included as negative controls. After a 24h incubation, NF-κB activation was determined using QUANTI-Blue™, a SEAP detection reagent, and by reading the optical density (OD) at 655 nm.


Stimulation of HCT116-Dual™ cells with the STING agonist 2'3'-cGAMP (30 µg/ml) or RLR ligands, such as transfected poly(I:C) (100 ng/ml) or poly(dA:dT) (100 ng/ml), triggers the IRF pathway. IFN-α (1x104 U/ml) has been included as a positive control to activate the IRF signaling pathway. Non-induced cells (NI), the TLR2 ligand (Pam3CSK4; 300 ng/ml), and the TLR4 ligand (LPS-EB Ultrapure; 104 EU/ml) have been included as negative controls. After a 24h incubation, IRFactivation was determined by measuring the relative light units (RLUs) in a luminometer using QUANTI-Luc™, a Lucia luciferase detection reagent

Back to the top

Specifications

Antibiotic resistances: Zeocin™, blasticidin

Guaranteed mycoplasma-free

Quality Control:

  • The stability of this cell line for 20 passages following thawing has been verified.
  • For each lot, proper activation of the NF-κB pathway and IRF pathway is confirmed upon stimulation of HCT116-Dual™ cells by various pathogen associated molecular patterns (PAMPs) known to activate these pathways.

 

This product is covered by a Limited Use License (See Terms and Conditions).

Back to the top

Contents

Shipped on dry ice (Europe, USA & Canada)

See Data Sheet for storage conditions of each component.

Back to the top

Description

HCT116-Dual™ cells express numerous pattern recognition receptors (PRRs), including the NOD-like receptors (NLRs) NOD1 and NOD2 [1, 2], the RIG-I-like receptor (RLR) RIG-I [3, 4], and the Toll-like receptors (TLRs) TLR3 and TLR5 [5] but not TLR2 or TLR4 [2].

Upon recognition of their cognate PAMPs, these receptors induce signaling pathways leading to the activation of the transcription factors NF-kB and/or IRF3/7. Stimulation of HCT116-Dual™ cells with the following PAMPs, Poly(I:C) (TLR3), flagellin (TLR5), Tri-DAP (NOD1), and MDP (NOD2), leads to the activation of NF-kB. Stimulation with RLR ligands, such as transfected poly(I:C) or poly(dA:dT), or the STING agonist, 2’3’-cGAMP, triggers the IRF pathway.
Stimulation with RLR ligands, such as transfected poly(I:C) or poly(dA:dT), or the STING agonist, 2’3’-cGAMP, triggers the IRF pathway.

HCT116-Dual™ cells are resistant to the selectable markers blasticidin and Zeocin™.

 

1. Rickard DJ. et al., 2014. Identification of selective small molecule inhibitors of the nucleotide-binding oligomerization domain 1 (NOD1) signaling pathway. PLoS One. 9(5):e96737.
2. Zhao L. et al., 2007. Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. J Biol Chem. 282(16):11618-28.
3 Gack MU. et al., 2008. Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. PNAS. 105(43):16743-8.
4. Taura M. et al., 2008. p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines. Mol Cell Biol. 28(21):6557-67.
5. Klimosch SN. et al., 2013. Functional TLR5 genetic variants affect human colorectal cancer survival. Cancer Res. 73(24):7232-42.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty